Foghorn Therapeutics(FHTX) - 2022 Q4 - Annual Report

Item 10. Directors, Executive Officers and Corporate Governance 103 Item 11. Executive Compensation 103 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 103 Item 13. Certain Relationships and Related Transactions, and Director Independence 103 Item 14. Principal Accountant Fees and Services 103 ITEM 1. BUSINESS 6 Table of Contents 3 Foghorn's science and potential have been validated by strategic collaborations with two world-leading pharmaceutical comp ...